Drugs / HSD-016
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00740649 | Oct 2008 → Mar 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00838461 Comparator | Mar → Jun 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00739232 Comparator | Sep 2008 → Feb 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSD-016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00838461 ↗ |
| Modality | Small molecule | — CHEMBL4297286 ↗ |
| Route | Oral | “Administered Orally to Healthy Subjects” NCT00739232 ↗ |